F. Buttitta

发表

Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients.

A. Marchetti, N. Tinari, F. Buttitta, 2002, Cancer research.

Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.

M Ferdeghini, F. Buttitta, A. Gadducci, 1999, Gynecologic oncology.

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.

A. Marchetti, F. Buttitta, P. Nuciforo, 2007, The Journal of clinical investigation.

p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.

A. Harris, A. Marchetti, F. Buttitta, 1996, British Journal of Cancer.

A Unique MicroRNA Signature Associated With Plaque Instability in Humans

Antonio Marchetti, A. Marchetti, F. Buttitta, 2011, Stroke.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

A. Marchetti, F. Buttitta, P. Visca, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survivin gene expression in early‐stage non‐small cell lung cancer

A. Marchetti, F. Buttitta, S. Bosari, 2003, The Journal of pathology.

Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network

F. Buttitta, G. Fontanini, M. Fassan, 2021, Pathologica.

Biomarkers in the diagnosis and treatment of malignant pleural disease: an integrative review

F. Buttitta, E. D'angelo, A. di Lorito, 2020 .

Alterations of P16 (MTS1) in node‐positive non‐small cell lung carcinomas

A. Marchetti, F. Buttitta, A. Chella, 1997, The Journal of pathology.

FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K‐ras mutations

A. Marchetti, F. Buttitta, A. Chella, 1998, The Journal of pathology.

Down Regulation of High in Normal-1 (HIN-1) is a Frequent Event in Stage I Non-Small Cell Lung Cancer and Correlates with Poor Clinical Outcome

A. Marchetti, F. Buttitta, A. Chella, 2004, Clinical Cancer Research.

Reduced expression of INT-6/eIF3-p48 in human tumors.

A. Marchetti, F. Buttitta, R. Callahan, 2001, International journal of oncology.

The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas.

A. Marchetti, F. Buttitta, H. Nevanlinna, 1997, Genomics.

Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors

A. Marchetti, F. Buttitta, R. Callahan, 1991, Journal of virology.

HostGenetic Background Effect ontheFrequency ofMouse MammaryTumorVirus-Induced Rearrangements oftheint-i andint-2 LociinMouseMammaryTumors

F. Buttitta, R. Callahan, G. Campbell, 1991 .

NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies

A. Marchetti, F. Buttitta, E. D'angelo, 2022, Pathologica.

Evaluation of FHIT gene alterations in ovarian cancer.

A. Marchetti, F. Buttitta, A. Gadducci, 1998, British Journal of Cancer.

Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus.

A. Marchetti, F. Buttitta, A. Chella, 1998, British Journal of Cancer.

mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations.

A. Marchetti, F. Buttitta, A. Chella, 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Practical Advices About How To Handle Disease Progression During Osimertinib In EGFR-Mutant NSCLC Patients: Is It The Same Old Story? A Mini Review

A. Marchetti, F. Buttitta, C. Ficorella, 2018 .

BRONCHIOLOALVEOLAR LUNG CARCINOMAS: K‐ras MUTATIONS ARE CONSTANT EVENTS IN THE MUCINOUS SUBTYPE

A. Marchetti, F. Buttitta, A. Chella, 1996, The Journal of pathology.

Int6 Expression Can Predict Survival in Early-Stage Non–Small Cell Lung Cancer Patients

A. Marchetti, F. Buttitta, A. Chella, 2005, Clinical Cancer Research.

Cyclin D1 and retinoblastoma susceptibility gene alterations in non‐small cell lung cancer

A. Marchetti, F. Buttitta, A. Chella, 1998, International journal of cancer.

Association between cigarette smoking and FHIT gene alterations in lung cancer.

A. Marchetti, F. Buttitta, A. Chella, 1997, Cancer research.

p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation.

A. Marchetti, F. Buttitta, A. Chella, 1996, Oncogene.

HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.

A. Marchetti, F. Buttitta, M. Roncalli, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

HER-2 / Neu Alterations in Non-Small Cell Lung Cancer : A Comprehensive Evaluation by Real Time Reverse Transcription-PCR , Fluorescence in Situ Hybridization , and Immunohistochemistry 1

A. Marchetti, F. Buttitta, M. Roncalli, 2003 .

p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.

F. Buttitta, A. Gadducci, A. Fanucchi, 2000, Anticancer research.

mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients

A. Marchetti, F. Buttitta, F. Mucilli, 2001, The Journal of pathology.

Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung

Antonio Marchetti, Giuseppe Pelosi, Fabio Barassi, 2008, Human mutation.

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

A. Marchetti, F. Buttitta, F. Cappuzzo, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduction of atherothrombotic burden before stent deployment in non‐ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose‐dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study

R. de Caterina, F. Buttitta, F. Prati, 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

A. Marchetti, F. Buttitta, M. Fassan, 2022, ESMO open.

p53 Mutations and Histologie Type of Invasive Breast Carcinoma

A. Marchetti, F. Buttitta, F. Diella, 1993, Cancer research.

Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31.

A. Marchetti, F. Buttitta, G. Bevilacqua, 1995, International journal of oncology.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories

A. Marchetti, F. Buttitta, P. Radice, 2019, Diagnostics.

Enriched SSCP: A Highly Sensitive Method for the Detection of Unknown Mutations. Application to the Molecular Diagnosis of Lung Cancer in Sputum Samples

A. Marchetti, F. Buttitta, G. Merlo, 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.

A. Marchetti, F. Buttitta, F. Mancini, 2005, Cancer research.

Mutations and Histological Type of Invasive Breast Carcinoma I

A. Marchetti, F. Buttitta, F. Diella, 2007 .

Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record

A. Marchetti, F. Buttitta, G. Fontanini, 2020, Cancers.

Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

A. Marchetti, F. Buttitta, S. Rosini, 2012, Clinical Cancer Research.

Multidrug resistance related genes and p53 expression in human non small cell lung cancer.

A. Marchetti, F. Buttitta, G. Bevilacqua, 1998, Anticancer research.

The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome.

A. Marchetti, F. Buttitta, D. Gallahan, 1995, Genomics.

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Antonio Marchetti, Keith T Flaherty, Dennie T Frederick, 2015, Nature Genetics.

Full cost of diagnostic pathology for lung carcinoma in Italy: results from four Pathology Units.

A. Marchetti, F. Buttitta, M. Papotti, 2023, Pathologica.

Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas

A. Marchetti, F. Buttitta, M. Barbareschi, 2007, Clinical Cancer Research.

Assessing EGFR mutations.

A. Marchetti, F. Buttitta, L. Felicioni, 2006, The New England journal of medicine.

PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma

A. Marchetti, F. Buttitta, F. Cuccurullo, 2006, The Journal of pathology.

Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia

A. Marchetti, F. Buttitta, D. Gallahan, 1995, Journal of virology.

microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer

Marta Di Nicola, Antonio Marchetti, A. Marchetti, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors

A. Marchetti, F. Buttitta, W. Vandertop, 2009, Human mutation.

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features

Antonio Marchetti, Fabio Barassi, A. Marchetti, 2006, International journal of cancer.

Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy.

P Boracchi, P Dalla Palma, A. Marchetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

A. Marchetti, F. Buttitta, A. Chella, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alterations in Non-Small Cell Lung Cancers Correlate with Metastatic Involvement of Hilar and Mediastinal Lymph Nodes 1

F. Buttitta, C. Angeletti, G. Merlo, 2006 .

p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes.

A. Marchetti, F. Buttitta, A. Chella, 1993, Cancer research.

Prediction of Survival in Stage I Lung Carcinoma Patients by Telomerase Function Evaluation

A. Marchetti, F. Buttitta, A. Chella, 2002, Laboratory Investigation.

Detection of p53 Mutations by Single‐strand Conformation Polymorphisms (SSCP) Gel Electrophoresis: A Comparative Study of Radioactive and Nonradioactive Silver‐stained SSCP Analysis

M. Loda, A. Marchetti, F. Buttitta, 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

A. Marchetti, F. Buttitta, G. Rossi, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma.

A. Marchetti, F. Buttitta, A. Gadducci, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.

A. Marchetti, F. Buttitta, A. Gadducci, 1997, British Journal of Cancer.

Predictive markers in lung cancer: a few hints for the practicing pathologist.

A. Marchetti, F. Buttitta, G. Fontanini, 2018, Pathologica.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD‐L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors

A. Marchetti, F. Buttitta, G. Scagliotti, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications

A. Marchetti, F. Buttitta, F. Mucilli, 2012, PloS one.

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations

A. Marchetti, F. Buttitta, E. D'angelo, 2022, Oncotarget.

ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.

A. Marchetti, F. Buttitta, F. Mucilli, 2017, JCO precision oncology.

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

Antonio Marchetti, A. Marchetti, F. Buttitta, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle.

A. Marchetti, F. Buttitta, A. di Lorito, 2017, Journal of thoracic disease.

Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas.

A. Marchetti, F. Buttitta, R. Lidereau, 1996, British Journal of Cancer.

AKT1E17K in human solid tumours

A. Marchetti, F. Buttitta, S. Leenstra, 2008, Oncogene.

Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.

A. Marchetti, F. Buttitta, A. Chella, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Association Between Prostaglandin E Receptor Subtype EP4 Overexpression and Unstable Phenotype in Atherosclerotic Plaques in Human

A. Marchetti, F. Buttitta, F. Cipollone, 2005, Arteriosclerosis, thrombosis, and vascular biology.

MDM4 (MDMX) localizes at the mitochondria and facilitates the p53‐mediated intrinsic‐apoptotic pathway

A. Marchetti, F. Buttitta, F. Mancini, 2009, The EMBO journal.

Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

Renzo Boldorini, Antonio Marchetti, Francesca Molinari, 2011, Clinical Cancer Research.

An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments

A. Marchetti, F. Buttitta, L. Felicioni, 2019, Oncotarget.

Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control.

F. Buttitta, A. Consoli, F. Cipollone, 2014, The Journal of clinical endocrinology and metabolism.

Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays.

A. Marchetti, F. Buttitta, F. Mucilli, 2016, Lung cancer.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

A. Marchetti, F. Buttitta, F. Cappuzzo, 2014, Clinical lung cancer.

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme

A. Marchetti, F. Buttitta, G. Scagliotti, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

A. Marchetti, F. Buttitta, C. Ficorella, 2019, OncoTargets and therapy.

Prognostic Value of 21 wAF 1 and p 53 Expression in Breast Carcinoma : An Immunohistochemical Study in 261 Patients with Long-Term Follow-Up

A. Harris, A. Marchetti, F. Buttitta, 2005 .

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

A. Marchetti, F. Buttitta, S. Iacobelli, 2009, Neoplasia.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

A. Marchetti, F. Buttitta, A. Chella, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

A. Marchetti, F. Buttitta, A. Chella, 2014, PloS one.

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment

A. Marchetti, F. Buttitta, A. Cortellini, 2020, Oncotarget.

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients.

A. Marchetti, F. Buttitta, G. Rossi, 2020, Critical reviews in oncology/hematology.

mdm2 gene alterations and mdm2 protein expression in breast carcinomas

A. Marchetti, F. Buttitta, M. Barbareschi, 1995, The Journal of pathology.

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.

A. Marchetti, F. Buttitta, G. Rossi, 2014, Lung cancer.

Human T elomerase R everse T ranscriptase m RNA E xpression Assessed b y R eal-Time R everse T ranscription P olymerase Chain R eaction P redicts C hemosensitivity i n P atients W ith Ovarian C arcinoma

A. Marchetti, F. Buttitta, A. Gadducci, 2003 .

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

A. Marchetti, F. Buttitta, G. Rossi, 2012 .

Mutational Profile of GNAQ Q209 in Human Tumors

A. Marchetti, F. Buttitta, A. Bardelli, 2009, PloS one.

Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.

A. Harris, A. Marchetti, F. Buttitta, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

A. Marchetti, F. Buttitta, F. Mucilli, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of DNA mutations in acid formalin-fixed paraffin-embedded archival tumor specimens by polymerase chain reaction-single strand conformation polymorphism analysis.

A. Marchetti, F. Buttitta, G. Merlo, 1995, Cancer detection and prevention.

Identification of microRNAs 758 and 33b as potential modulators of ABCA1 expression in human atherosclerotic plaques.

F. Buttitta, F. Cipollone, M. Bucci, 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Analysis of failures in patients with stage I ovarian cancer: an Italian multicenter study

F. Buttitta, E. Sartori, F. Landoni, 1997 .

Cyclin‐d1‐gene amplification and expression in breast carcinoma: Relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21waf1 immunohistochemical expression

A. Marchetti, F. Buttitta, M. Barbareschi, 1997, International journal of cancer.

Microsatellite alterations and p53, TGFβRII, IGFIIR and BAX mutations in sporadic non‐small‐cell lung cancer

A. Marchetti, F. Buttitta, G. Bevilacqua, 1998, International journal of cancer.

Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

F. Buttitta, P. Amerio, R. Patea, 2017, International medical case reports journal.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

A. Marchetti, F. Buttitta, P. Radice, 2019, Critical reviews in oncology/hematology.

The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.

A. Marchetti, F. Buttitta, A. Paradiso, 2009, The International journal of biological markers.

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy

A. Marchetti, F. Buttitta, M. Seckl, 2013, Virchows Archiv.

POLE exonuclease domain mutations in endometrial carcinoma: a case report.

A. Marchetti, F. Buttitta, M. Barbareschi, 2023, Pathologica.

Imaging , Diagnosis , Prognosis Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing

A. Marchetti, F. Buttitta, S. Rosini, 2013 .

A. Marchetti, F. Buttitta, G. Viale, 1998, Laboratory investigation; a journal of technical methods and pathology.

Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.

F. Buttitta, A. Gadducci, A. Fanucchi, 1996, Anticancer Research.

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer12

A. Marchetti, F. Buttitta, G. Gasparini, 2014, Neoplasia.

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced

A. Marchetti, F. Buttitta, G. Gasparini, 2014 .

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

A. Marchetti, F. Buttitta, A. Chella, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control.

F. Buttitta, A. Consoli, F. Cipollone, 2014, The Journal of clinical endocrinology and metabolism.

A Unique MicroRNA Signature Associated With Plaque Instability in Humans

A. Marchetti, F. Buttitta, F. Cipollone, 2011, Stroke.

Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer.

A. Marchetti, F. Buttitta, A. Chella, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.

A. Marchetti, F. Buttitta, S. Buti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network

A. Marchetti, F. Buttitta, A. Scarpa, 2020, Journal of Clinical Pathology.